DK169018B1 - Anvendelse af sulfaterede sukkerarter - Google Patents
Anvendelse af sulfaterede sukkerarter Download PDFInfo
- Publication number
- DK169018B1 DK169018B1 DK005792A DK5792A DK169018B1 DK 169018 B1 DK169018 B1 DK 169018B1 DK 005792 A DK005792 A DK 005792A DK 5792 A DK5792 A DK 5792A DK 169018 B1 DK169018 B1 DK 169018B1
- Authority
- DK
- Denmark
- Prior art keywords
- disaccharide
- sulfated
- mono
- use according
- salt
- Prior art date
Links
- 150000002016 disaccharides Chemical class 0.000 claims abstract description 30
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 27
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 230000000699 topical effect Effects 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 claims description 25
- 229960004291 sucralfate Drugs 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 19
- 150000001720 carbohydrates Chemical class 0.000 claims description 16
- WEPNHBQBLCNOBB-FZJVNAOYSA-N sucrose octasulfate Chemical group OS(=O)(=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@H](COS(=O)(=O)O)O[C@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 WEPNHBQBLCNOBB-FZJVNAOYSA-N 0.000 claims description 13
- 239000002674 ointment Substances 0.000 claims description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 8
- 229920002674 hyaluronan Polymers 0.000 claims description 7
- 229960003160 hyaluronic acid Drugs 0.000 claims description 7
- 229910052782 aluminium Inorganic materials 0.000 claims description 6
- 210000002808 connective tissue Anatomy 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 230000037303 wrinkles Effects 0.000 claims description 5
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 229910052788 barium Inorganic materials 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 229910052748 manganese Inorganic materials 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 210000002200 mouth mucosa Anatomy 0.000 claims description 3
- 229910052762 osmium Inorganic materials 0.000 claims description 3
- 230000009759 skin aging Effects 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 229910052726 zirconium Inorganic materials 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 230000002496 gastric effect Effects 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 208000035475 disorder Diseases 0.000 abstract description 3
- 238000001356 surgical procedure Methods 0.000 abstract description 2
- 230000000813 microbial effect Effects 0.000 abstract 2
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- 206010004146 Basal cell carcinoma Diseases 0.000 abstract 1
- 206010048768 Dermatosis Diseases 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 206010073306 Exposure to radiation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000019065 cervical carcinoma Diseases 0.000 abstract 1
- 239000013043 chemical agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000003914 endometrial carcinoma Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 238000002513 implantation Methods 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 201000004700 rosacea Diseases 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 238000007910 systemic administration Methods 0.000 abstract 1
- 210000004291 uterus Anatomy 0.000 abstract 1
- 210000001508 eye Anatomy 0.000 description 20
- 239000002245 particle Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 7
- -1 saccharide sucrose octasulfate Chemical class 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 235000019864 coconut oil Nutrition 0.000 description 4
- 239000003240 coconut oil Substances 0.000 description 4
- 210000000795 conjunctiva Anatomy 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000001814 pectin Substances 0.000 description 4
- 235000010987 pectin Nutrition 0.000 description 4
- 229920001277 pectin Polymers 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 102000001974 Hyaluronidases Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108050009363 Hyaluronidases Proteins 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000007970 homogeneous dispersion Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000000554 iris Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
- 229940100615 topical ointment Drugs 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000086254 Arnica montana Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000013913 Ceratonia Nutrition 0.000 description 1
- 241001060815 Ceratonia Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229920002201 Oxidized cellulose Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000000504 antifibrinolytic agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 229940043431 ceratonia Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 229960001275 dimeticone Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940063644 ispaghula husk Drugs 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000051 modifying effect Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229940100656 nasal solution Drugs 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940107304 oxidized cellulose Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- MBTJHFXKYOUFMC-UJPDDDSFSA-N sulfuric acid;(2r,3s,4r)-2,3,4,5-tetrahydroxypentanal Chemical compound OS(O)(=O)=O.OC[C@@H](O)[C@H](O)[C@@H](O)C=O MBTJHFXKYOUFMC-UJPDDDSFSA-N 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940098956 topical powder Drugs 0.000 description 1
- 230000001562 ulcerogenic effect Effects 0.000 description 1
- 230000009677 vaginal delivery Effects 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/26—Aluminium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/58—Metal complex; Coordination compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Cosmetics (AREA)
- Seasonings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polymerisation Methods In General (AREA)
Description
DK 169018 B1
Den foreliggende opfindelse angår anvendelsen af et sulfa-teret mono- eller disaccharid eller et salt eller kompleks deraf til fremstilling af et præparat til topisk applikation til forebyggelse eller behandling af ældning af hud, binde-5 væv, non-orale epiteloverflader eller non-orale mukosa, herunder til forebyggelse eller behandling af hudrynker.
Sulfaterede saccharider, primært sukralfat, er tidligere blevet indiceret til behandling af gastriske og duodenale ulcus (jvnf. US patentskrift nr. 3.432.489/ EP patentskrift 10 nr. 161816; EP patentskrift nr. 192640) og til behandling af emesis og diarré i hunde og katte (jvnf. EP patentskrift nr. 133880). I radioaktiv mærket form er sukralfat også brugt som diagnostisk middel til visualisering af gastrointestinal mukosa, idet stoffet selektivt bindes til ulcererede områder 15 i maven og den øvre tyndtarm (jvnf. EP patentskrift nr.
107209).
I The American Journal of Gastroenterology, 80(3), 1985, side 206209; "Sucralfate: New Aspects in Therapy of Ulcers and Lesions" og i "Second International Sucralfate Symposium 20 Together With the World Congress of Gastroenterology in Stockholm" foreslås anvendelsen af sukralfat til en række non-ulcus-områder, deriblandt behandling af stomatitis, post-skierotisk ulcus, reflux oesophagitis og galde-reflux oesophagitis samt til modvirkning af de ulcerogene effekter 25 af aspirin.
Det har overraskende vist sig, at polysulfaterede mono- og disaccharider udøver meget interessante effekter, når de anvendes topisk på huden og slimhindeoverflader.
Den foreliggende opfindelse angår således i ét aspekt an-30 vendelse af et sulfateret mono- eller disaccharid eller et salt eller et kompleks deraf til fremstilling af et præparat til topisk applikation på huden eller en hvilken som helst non-gastrointestinal, non-oral slimhindeoverflade hos et dyr eller et menneske til forebyggelse eller behandling af æld- 2 DK 169018 B1 ning af hud, bindevæv eller non-orale mukosaoverflader, herunder til forebyggelse eller behandling af hudrynker.
EP patentskrift nr. 230023 angår anvendelse af sulfaterede saccharider til forbedring af sårheling. Det fremgår heraf, 5 at sukralfat giver anledning til inflammatoriske reaktioner, når det påføres sår. Det er også anført, at der foretrækkes lave niveauer på 0,1-1,0 mg/ml af det polysulfaterede sac-charid sukrose-oktasulfat i form af kaliumsaltet deraf for at undgå lokal hæmorragi eller inflammation i sårområdet.
10 Kliniske undersøgelser i dyr har vist, at kaliumsaltet af sukrose-oktasulfat er veltolereret, når det påføres topisk i kirurgiske sår, og når det gives som intravenøs injektion. I forbindelse med kirurgiske indgreb fik hunde og katte postoperativt en opløsning af 20 mg/ml af kaliumsaltet af sukro-15 se-oktasulfat i en dosis på 5 mg/kg legemsvægt. Der observeredes en hurtig normalisering af temperatur, og sårhelingen var uden suppuration eller inflammation.
Tolerancen af en 2% vandig suspension af mikroniseret sukralfat er undersøgt i en kaninøjemodel. Der var ingen tegn på 20 nogen form for irritation eller inflammatoriske reaktioner i konjunktiva, cornea eller øjenomgivelser, og det konkludere-des, at testpræparatet ikke var øjenirritativt (eksempel 9).
Sukralfat, som er aluminiumskomplekset af sukrose-oktasulfat, udviser en overordentlig god tolerance, dokumenteret gennem 25 et totalt fravær af bivirkninger efter anvendelse til behandling af peptisk ulcus, og både sukralfat og sukrose-oktasulfat har vist en meget god tolerance brugt topisk på huden og slimhinder.
Det er tænkeligt, at sulfaterede saccharider såsom sukrose-30 oktasulfat modificerer eller hæmmer inflammatoriske reaktioner og/eller stimulerer vævsregenerative processer via andre, endnu ikke fuldt klarlagte mekanismer.
DK 169018 B1 3
Det er observeret, at ét sulfateret saccharid, nemlig sukral-fat, når det anvendes internt ved behandling af peptiske ulcus, fortrinsvis binder sig til selve ulcusoverfladen. Det antages for tiden, at dette er en egenskab, som er fælles for 5 sulfaterede saccharider, og at denne binding skyldes sulfa-terede sacchariders evne til at binde sig til proteoglykaner og hyaluronsyre. Disse strukturer er overfladekomponenter hos mange celler, og de beskytter og stabiliserer cellen og er med til at opretholde den ydre celleoverflade intakt. I andre 10 tilfælde, fx i dermis og i bindevæv, udgør proteoglykaner og hyaluronsyre en beskyttende matrix, i hvilken cellerne er indlejret. Ydermere er det kendt, at visse sulfaterede saccharider, fx heparansulfat, dextransulfat og xylosesulfat, er hyaluronidase-inhibitorer.
15 Hyaluronidaser er enzymer, som katalytisk spalter glykosid-bindingerne i hyaluronsyre og glykosaminoglykaner. Hyaluroni-dasers nedbrydning af hyaluronsyre og glykosaminoglykaner indebærer derfor, at cellerne via ødelæggelse af celleoverfladen eller bindevævsmatricen eksponeres for og beskadiges 20 af forskellige agens såsom patogener, inflammatoriske me-diatorsubstanser, inflammatoriske og korrosive agens. Det antages således, at sulfaterede saccharider ved hæmning af hyaluronidaser fremmer regeneration af celleoverfladen og den beskyttende bindevævsmatrix og derigennem udøver en anti-in-25 flammatorisk og vævsregenererende virkning.
Nedbrydningsprodukter af hyaluronsyre og glykosaminoglykaner kan også i sig selv fungere som mediatorsubstanser for inflammation, og via hæmning eller modifikation af denne nedbrydning kan sukrose-oktasulfat og andre sulfaterede sac-30 charider udøve en hæmmende eller modificerende effekt på inflammatoriske reaktioner og lette og modificere vævsregeneration.
Det antages således, at de ovennævnte farmakologiske effekter af sukrose-oktasulfat og andre sulfaterede saccharider resul-35 terer i en "styrkelse" af epitel- og mukosaoverflader. Ud 4 DK 169018 B1 over at udøve en antiinflammatorisk effekt betyder denne styrkelse af den ydre celleoverflade og bindevævscellematricen også, at det vil være vanskeligere for bakterier og virus at gennemtrænge og kolonisere cellerne og vævet.
5 De sulfaterede saccharider, der anvendes i forbindelse med opfindelsen, kan være et monosaccharid, fx xylose, fruktose eller glukose eller et disaccharid såsom sukrose, laktose, maltose eller cellobiose. I visse tilfælde kan det være en fordel at anvende det sulfaterede mono- eller disaccharid i 10 kombination med et ikke-sulfateret polysaccharid, fx hyal-uronsyre (eksempel 7) .
Mono- eller disaccharidet er fortrinsvis et polysulfateret eller persulfateret saccharid, hvilket betyder, at to eller flere, eventuelt alle, svovlholdige enheder er til stede som 15 substituenter på carbonhydratenheder.
I nogle tilfælde kan det sulfaterede mono- eller disaccharid være i form af et kompleks eller danne et salt med et metal, fx et alkali- eller jordalkalimetal såsom Na, K, Ca, Mg eller Ba, eller Al, Zn, Cu, Zr, Ti, Bi, Mn eller Os, eller med en 20 organisk base (fx en aminosyre). De foretrukne salte er kalium- og natriumsalte.
Præparatet indeholder fortrinsvis et persulfateret disaccharid, eventuelt sukrose-oktasulfat.
Substansen kan fx fremstilles som anført i EP patentskrift 25 nr. 230023.
Selv om der kan være tilfælde, hvor det sulfaterede monoeller disaccharid kan administreres som sådant, vil det typisk være formuleret sammen med én eller flere farmaceutisk acceptable bærere eller hjælpestoffer, så det fremtræder i en 30 form, der er egnet til topisk applikation. Med andre ord vil det være i form af et flydende, halvfast eller fast topisk præparat såsom et pulver, en pasta, en salve, en lotion, en DK 169018 B1 5 gel, en creme, en emulsion, en opløsning, en suspension, en spray, en svamp, en strimmel, et plaster, en pude, en forbinding eller en stomiplade.
Til topisk applikation kan præparatet formuleres ifølge 5 konventionelle farmaceutiske principper med anvendelse af farmaceutiske hjælpestoffer, som konventionelt benyttes i forbindelse med topiske anvendelser, såsom pektin, gelatine og derivater deraf, polymælkesyre- eller polyglycolsyrepolymerer eller -copolymerer deraf, cellulosederivater såsom 10 methylcellulose, carboxymethylcellulose eller oxideret cellulose, guargummi, acaciegummi, karayagummi, traganthgummi, bentonit, agar, carbomer, blæretang, ceratonia, dextran og derivater deraf, ghattigummi, hectorit, ispaghula husk, polyvinylpyrrolidon, siliciumdioxid og derivater deraf, 15 xanthangummi, kaolin, talkum, stivelse og derivater deraf, paraffin, vand, vegetabilske og animalske olier, polyethylen, polyethylenoxid, polyethylenglycol, polypropylenglycol, glycerol, ethanol, propanol, propylenglycol (glycoler og alkoholer) , faste olier, natrium-, kalium-, aluminium-, magne-20 sium- eller calciumsalte (såsom chlorider, carbonater, hydro-gencarbonater, citrater, gluconater, lactater, acetater, gluceptater eller tartrater).
Præparatet fremstillet kan også indeholde andre additiver såsom emulgatorer, stabiliseringsmidler, konserveringsmidler, 25 etc.
Plastre, svampe, strimler, puder eller andre former for forbindinger kan fremstilles ved at imprægnere et forbindingsmateriale såsom bomuld eller gaze eller en polymersubstans med en opløsning eller en suspension af det sulfaterede 30 mono- eller disaccharid, efterfulgt af tørring. Alternativt kan en pasta, lotion, creme eller gel indeholdende det sulfaterede mono- eller disaccharid spredes ud over forbindings-materialet, hensigtsmæssigt umiddelbart inden brugen.
6 DK 169018 B1
Til application på slimhinder, eksempelvis vaginal-, næse- og øjenslimhinder, kan præparatet fx formuleres i form af et vagitorie, en gel, en salve, en opløsning eller en suspension eller en indretning til vaginal indføring, en nasal opløs-5 ning, suspension, gel, salve eller en indretning til nasal indføring eller en øjenopløsning, øjensuspension, øjengel, øjensalve eller en indretning til indføring i øjet. Sådanne formuleringer kan fremstilles ifølge konventionelle farmaceutiske principper under anvendelse af konventionelle hjæl-10 pestoffer såsom nogle af de ovenfor anførte.
Præparatet fremstillet ifølge opfindelsen omfatter sædvanligvis det sulfaterede mono- eller disaccharid i en mængde på 0,001-99 vægtprocent, typisk 0,01-75 vægtprocent, mere typisk 0,1-20 vægtprocent, specielt 1-10 vægtprocent, af det samlede 15 præparat. I særdeleshed når det sulfaterede mono- eller disaccharid er sukrose-oktasulfat, er en foretrukken koncentration deraf i præparatet ofte 0,5-50 vægtprocent, specielt 0,5-25 vægtprocent såsom 1-10 vægtprocent. Det appliceres hensigtsmæssigt 1-10 gange i døgnet, afhængig af type 20 og sværhedsgrad af den lidelse, der skal behandles.
Den koncentration af det sulfaterede mono- eller disaccharid, som anvendes i hvert enkelt tilfælde, vil naturligvis afhænge af præparattypen og det tiltænkte formål, men vil også afhænge af det sulfaterede mono- eller disaccharids opløse-25 lighedskarakteristika og for tungtopløselige og i det væsentlige uopløselige sulfaterede mono- og disaccharider tillige af deres partikelstørrelse; desto mindre partikelstørrelse, desto hurtigere vil opløsningen af selv tungtopløselige eller i det væsentlige uopløselige sulfaterede mono- og disaccha-30 rider eller komplekser deraf være. Uopløselige eller tungtopløselige salte eller komplekser af sulfaterede saccharider anvendes fortrinsvis i form af et fint pulver, fx med en partikelstørrelse på 200 μτη eller mindre, såsom 100 μιη eller mindre. Eksempler på meget små partikelstørrelser, som kan 35 være ønskelige til bestemte formål, er eksempelvis 50 μπι DK 169018 B1 7 eller mindre, såsom 20 μτη eller mindre, i visse tilfælde 10 μπι eller mindre, såsom 5 μτη eller mindre.
Præparatet kan indeholde andre aktive midler end det sulfa-terede mono- eller disaccharid såsom antibakterielle midler, 5 antivirale midler, antiparasitære midler, solbeskyttelsesmidler, vitaminer og vitaminderivater eller -analoger, anti-neoplastiske midler, antimykotiske midler, antifibrinolytiske midler, blodkoagulationsmodificerende midler, antiseptiske midler, analgetika, topiske anæstetika eller anti-inflamma-10 toriske midler.
Specifikke tilstande, for hvilke anvendelsen af det sulfa-terede mono- eller disaccharid er indiceret, omfatter:
Kosmetisk over for rynker og hudældning, både som aktivt behandlende middel og som forbyggende middel.
15 Opfindelsen belyses yderligere af følgende eksempler.
EKSEMPEL 1
Et topisk pudderpræparat blev fremstillet ud fra følgende bestanddele:
Sukralfat* 30 gram 20 Pektin 10 gram
Gelatine 10 gram
Carboxymethylcellulose 10 gram *Leveret af Abic Laboratories, Israel, i findelt form.
Det findelte sukralfat (partikelstørrelse 2-100 μπι) blev 25 grundigt blandet med de øvrige bestanddele i findelt form (partikelstørrelse < 250 μτη) til fremstilling af et pulver.
DK 169018 B1 EKSEMPEL 2 8
Et topisk salvepræparat blev fremstillet ud fra følgende bestanddele:
Sukralfat 30 gram 5 Pektin 10 gram
Gelatine 10 gram
Carboxymethylcellulose 10 gram
Fraktioneret kokosnøddeolie 60 gram
Det findelte sukralfat (partikelstørrelse 2-100 μπι) blev 10 omhyggeligt blandet med de øvrige bestanddele i findelt form. Fraktioneret kokosnøddeolie blev tilsat det resulterende pulver til at give en passende konsistens og en i det væsentlige homogen dispersion af de partikelformige bestanddele.
EKSEMPEL 3 15 Et topisk salvepræparat blev fremstillet ud fra følgende bestanddele:
Sukralfat 30 gram
Hyaluronsyre 0,6 gram
Pektin 10 gram 20 Gelatine 10 gram CMC 10 gram
Fraktioneret kokosnøddeolie 60 gram
Det findelte sukralfat (partikelstørrelse 2-100 μιη) blev omhyggeligt blandet med de øvrige bestanddele i findelt form.
25 Fraktioneret kokosnøddeolie blev tilsat det resulterende pulver til at give en passende konsistens og en i det væsentlige homogen dispersion af de partikelformige bestanddele.
EKSEMPEL 4 DK 169018 B1 9
Et topisk øjenpræparat blev fremstillet ud fra følgende bestanddele:
Sukralfat* 2% 5 Carbopol 934 0,5%
Mannitol 5%
Benzalkoniumchlorid 0,01%
Natrium EDTA 0,05%
Natriumhydroxid q.s. ad pH 6 10 Sterilt vand ad 100% *Mikroniseret sukralfat (partikelstørrelse 10 μιη) leveret af Giulini Chemie, Vesttyskland.
EKSEMPEL 5 Øj enpræparat 15 Et øjenpræparat blev fremstillet ud fra følgende bestanddele:
Sukralfat* 2%
Propylmethylcellulose 0,35%
Benzalkoniumchlorid 0,01%
Natrium EDTA 0,05% 20 Natriumchlorid 0,8%
Sterilt vand q.s.
*Mikroniseret (10 μιη) leveret af Giulini Chemie, Lud-wigshafen, Vesttyskland.
EKSEMPEL 6 25 Et topisk præparat til hud og slimhinder blev fremstillet ved at blande 5 vægtprocent af et sukralfatpulver (partikelstør DK 169018 B1 10 relse 50-100 μπι, leveret af Giulini Chemie, Vesttyskland) med en blanding af ætanol, adeps lanae purificatae, isopropyl myristas, Tween 60, Span 60, dimeticon, glycerol, sorbinsyre og sterilt vand.
5 EKSEMPEL 7 A) Et topisk præparat til hud og slimhinder blev fremstillet ud fra følgende bestanddele:
Sukral fa tpul ver* 5%
Paraffinolier, glycerin, cetylalkohol 55% 10 Kvaternære ammoniumforbindelser 0,7%
Stearylalkohol 3%
Eukalyptusolie q.s.
*Mikroniseret sukralfat (<10 μπι) leveret af Giulini Chemie, Vesttyskland.
15 EKSEMPEL 8
Humane kliniske undersøgelser A) Fire kvinder med vulvovaginitis-symptomer var fri for pruritus efter behandling i 4 måneder som vist i nedenstående tabel 1 med topisk applikation af sukralfatsalve. Præparatet 20 omfattede 5 vægtprocent sukralfatpulver blandet i et fedt-vehikel bestående af urteekstrakter med kamille (6%) og arnika (4%). Salven blev appliceret morgen og aften. Ingen bivirkninger sås under behandlingen med sukral fat salve i denne periode.
Tabel 1 11 DK 169018 B1
Lidelse Antal Køn Alder Middel patienter testet i 5 Anal-vulval pruritus 4 F 48-71 4 mdr.
B) Sukralfatsalve som beskrevet i eksempel 8 A) blev testet ved behandling af ansigtsrynker omkring øjnene. Tre kvinder i alderen 38-45 år brugte salven to gange dagligt, og en gun-10 stig effekt sås efter 1-2 ugers behandling.
EKSEMPEL 9
Kaninøjentolerancetest for sukralfat-øjendråber
Den primære øjenirritative effekt af sukralfat-øjendråberne ifølge eksempel 5 blev undersøgt i kaniner. Undersøgelsen 15 blev udført på fire SPF-albinohunkaniner. Kun det venstre øje blev behandlet, og det højre øje tjente som ubehandlet kontrol. Ca. 0,1 ml af forsøgspræparatet blev appliceret i øjet ved forsigtigt at trække nederste øjenlåg bort fra øjenæblet og placere testsubstansen i den frembragte kavitet. Øjen-20 lågene blev herefter forsigtigt holdt sammen i ca. ét sekund. Øjnene blev inspiceret, og graden af øjenreaktion blev optegnet en time senere. 24 timer senere blev der udført en undersøgelse før og efter drypning med fluorescinøjendråber. Efter undersøgelsen blev øjnene skyllet med 20 ml af en 0,9% 25 natriumchloridopløsning. Øjnene blev også inspiceret 48 og 72 timer efter behandlingen. Cornea, iris og konjunktiva (incl. tåreflåd) blev undersøgt, og enhver form for reaktion og forandring blev noteret og scoret. Let udflåd af konjunktiva sås hos to kaniner ved den første undersøgelse. Der var ingen 30 reaktioner i konjunktiva, iris eller cornea hos nogen af kaninerne ved undersøgelsen efter 24, 48 og 72 timer.
Claims (10)
1. Anvendelse af et sulfateret mono- eller disaccharid eller et salt eller kompleks deraf til fremstilling af et præparat til topisk applikation til forebyggelse eller behandling af ældning af hud, bindevæv, non-orale epiteloverflader eller 15 non-orale mukosa, herunder til forebyggelse eller behandling af hudrynker.
2. Anvendelse ifølge krav 1, kendetegnet ved, at det sulfaterede saccharid er et monosaccharid valgt blandt xylose, fruktose og glucose.
3. Anvendelse ifølge krav 1, kendetegnet ved, at det sulfaterede saccharid er et disaccharid valgt blandt sukrose, laktose, maltose og cellobiose.
4. Anvendelse ifølge et hvilket som helst af kravene 1-3, 25 kendetegnet ved, at det sulfaterede mono- eller disaccharid er kombineret med et ikke sulfateret poly-saccharid, fx hyaluronsyre. DK 169018 B1
5. Anvendelse ifølge et hvilket som helst af kravene 1-4, kendetegnet ved, at det sulfaterede mono- eller disaccharid er et polysulfateret mono- eller disaccharid, fortrinsvis et persulfateret mono- eller disaccharid.
6. Anvendelse ifølge et hvilket som helst af kravene 1-5, kendetegnet ved, at det stof, hvormed det sulfaterede mono- eller disaccharid er kompleksbundet, eller hvormed det danner et salt, er et metal valgt blandt Al, Na, K, Ca, Mg, Ba, Zn, Cu, Zr, Ti, Bi, Mn og Os, eller en amino-10 syre.
7. Anvendelse ifølge krav 3, kendetegnet ved, at det sulfaterede disaccharid er sucrose oktasulfat, et kompleks eller salt af sucrose okta-sulfat med et metal valgt blandt Al, Na, K, Ca, Mg, Ba, Zn,
15 Cu, Zr, Ti, Bi, Mn og Os, eller et salt af sucrose oktasulfat med en aminosyre.
8. Anvendelse ifølge krav 7, kendetegnet ved, at det sulfaterede disaccharid er sucrose oktasulfat eller et natrium- eller kaliumsalt deraf 20 eller aluminiumkomplekset af sukrose oktasulfat, sukralfat.
9. Anvendelse ifølge et hvilket som helst af kravene 1-8, til fremstilling af et præparat til topisk brug i form af en pasta, en salve, en lotion, en gel, en creme, en emulsion, en opløsning, en suspension, en spray, en svamp eller en pude.
10. Anvendelse ifølge et hvilket som helst af kravene 1-9, kendetegnet ved, at koncentrationen af det sulfaterede mono- eller disaccharid i præparatet er 0,01-75 vægtprocent, typisk 0,1-20 vægtprocent, især 1-10 vægtprocent af præparatet.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK005792A DK169018B1 (da) | 1987-12-21 | 1992-01-17 | Anvendelse af sulfaterede sukkerarter |
| DK199400203A DK174560B1 (da) | 1987-12-21 | 1994-02-18 | Anvendelse af sulfaterede sukkerarter til fremstilling af et præparat til behandling af skæl |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK674087 | 1987-12-21 | ||
| DK674087A DK674087D0 (da) | 1987-12-21 | 1987-12-21 | Saarbehandlingsmiddel |
| DK505488A DK505488D0 (da) | 1987-12-21 | 1988-09-09 | Middel og anvendelse af samme |
| DK505488 | 1988-09-09 | ||
| DK005792A DK169018B1 (da) | 1987-12-21 | 1992-01-17 | Anvendelse af sulfaterede sukkerarter |
| DK5792 | 1992-01-17 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK5792A DK5792A (da) | 1992-01-17 |
| DK5792D0 DK5792D0 (da) | 1992-01-17 |
| DK169018B1 true DK169018B1 (da) | 1994-08-01 |
Family
ID=26067713
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK505488A DK505488D0 (da) | 1987-12-21 | 1988-09-09 | Middel og anvendelse af samme |
| DK151590A DK165357C (da) | 1987-12-21 | 1990-06-21 | Anvendelse af sulfaterede disaccharid eller et salt eller kompleks deraf til fremstilling af et laegemiddel til profylakse eller behandling af inflammation |
| DK151690A DK151690A (da) | 1987-12-21 | 1990-06-21 | Anvendelse af sucralfat |
| DK005792A DK169018B1 (da) | 1987-12-21 | 1992-01-17 | Anvendelse af sulfaterede sukkerarter |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK505488A DK505488D0 (da) | 1987-12-21 | 1988-09-09 | Middel og anvendelse af samme |
| DK151590A DK165357C (da) | 1987-12-21 | 1990-06-21 | Anvendelse af sulfaterede disaccharid eller et salt eller kompleks deraf til fremstilling af et laegemiddel til profylakse eller behandling af inflammation |
| DK151690A DK151690A (da) | 1987-12-21 | 1990-06-21 | Anvendelse af sucralfat |
Country Status (9)
| Country | Link |
|---|---|
| EP (3) | EP0394333B1 (da) |
| JP (2) | JPH04500797A (da) |
| KR (2) | KR930003117B1 (da) |
| AT (2) | ATE119778T1 (da) |
| AU (2) | AU631529B2 (da) |
| DE (2) | DE3853365T2 (da) |
| DK (4) | DK505488D0 (da) |
| HK (1) | HK56396A (da) |
| WO (2) | WO1989005645A1 (da) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK674087D0 (da) * | 1987-12-21 | 1987-12-21 | Bar Shalom Daniel | Saarbehandlingsmiddel |
| DK505488D0 (da) * | 1987-12-21 | 1988-09-09 | Bar Shalom Daniel | Middel og anvendelse af samme |
| US5202311A (en) * | 1988-08-19 | 1993-04-13 | Children's Medical Center Corporation | Stabilized fgf composition |
| US5618798A (en) * | 1989-04-20 | 1997-04-08 | Bar-Shalom; Daniel | Use of sucralfate to treat baldness |
| IT1230157B (it) * | 1989-06-16 | 1991-10-14 | Lisapharma Spa | Uso di sucralfato gel umido per il trattamento di ulcere del derma e come veicolo di farmaci ad attivita' topica |
| IL95642A0 (en) * | 1989-09-15 | 1991-06-30 | Pehrom Pharmaceutical Corp | Topical preparations for treatment of ulcers and other lesions |
| CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
| CA2090479C (en) * | 1990-08-31 | 2002-01-15 | Kiyoshige Ochi | Stock solution of sucralfate suspended in water and production thereof |
| US5639738A (en) * | 1992-02-20 | 1997-06-17 | Hyal Pharmaceutical Corporation | Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs |
| DE69120933T2 (de) * | 1991-04-18 | 1997-01-16 | Baldacci Lab Spa | Topische Anwendung von Glycosaminoglykane zur Prävention und Behandlung der Zervikal- oder Vaginalerkrankungen |
| US5817644A (en) * | 1991-07-03 | 1998-10-06 | Hyal Pharmaceutical Corporation | Targeting of dosages of medicine and therapeutic agents |
| US5990095A (en) * | 1991-07-03 | 1999-11-23 | Hyal Pharmaceutical Corporation | Use of hyaluronic acid and forms to prevent arterial restenosis |
| US5792753A (en) * | 1991-07-03 | 1998-08-11 | Hyal Pharmaceutical Corporation | Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs |
| IT1251151B (it) * | 1991-08-05 | 1995-05-04 | Fidia Spa | Materiale spugnoso essenzialmente costituito da acido ialuronico,o suoi derivati |
| US5942498A (en) * | 1992-02-20 | 1999-08-24 | Hyal Pharmaceutical Corporation | Formulations containing hyaluronic acid |
| US6114314A (en) * | 1992-02-21 | 2000-09-05 | Hyal Pharmaceutical Corp. | Formulations containing hyaluronic acid |
| CA2110176A1 (en) * | 1992-03-28 | 1993-10-14 | Akira Yanagawa | Topical preparation for healing wounds of the skin |
| US6750207B1 (en) * | 1992-05-01 | 2004-06-15 | Yeda Research And Development Co. Ltd. | Compositions for the regulation of cytokine activity |
| DK86492D0 (da) * | 1992-06-30 | 1992-06-30 | Bukh Meditec | Laegemiddel |
| AU6362594A (en) * | 1993-03-10 | 1994-09-26 | Miles Inc. | Hyaluronic acid used as a cancer treatment |
| US20040208875A1 (en) | 1995-03-15 | 2004-10-21 | Queen's University At Kingston | Method for treating amyloidosis |
| WO1994022437A2 (en) * | 1993-03-29 | 1994-10-13 | Queen's University At Kingston | Method for treating amyloidosis |
| US5434144A (en) * | 1994-03-04 | 1995-07-18 | The Procter & Gamble Company | Methods of using cyclic polyanionic polyol derivatives for regulating skin wrinkles |
| JP3981151B2 (ja) * | 1994-03-28 | 2007-09-26 | ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク | 液体中の刺激物を不活化するための組成物 |
| ATE213635T1 (de) * | 1994-04-26 | 2002-03-15 | Chugai Pharmaceutical Co Ltd | Verfahren für die herstellung schmelz-granulierte sucralfatzubereitung |
| SE9401826D0 (sv) * | 1994-05-27 | 1994-05-27 | Pharmacia Ab | Anti-Helicobacter pyroli substance |
| US5783568A (en) * | 1994-06-10 | 1998-07-21 | Sugen, Inc. | Methods for treating cancer and other cell proliferative diseases |
| EP0808629A4 (en) * | 1995-02-02 | 1998-03-04 | Chugai Pharmaceutical Co Ltd | Sucralfate preparation |
| DE69621528T2 (de) * | 1995-02-07 | 2003-01-16 | Shiseido Co. Ltd., Tokio/Tokyo | Anti-inflamatorische agenzien |
| US6537977B1 (en) * | 1995-09-19 | 2003-03-25 | Seikagaku Corporation | Anti-inflammatory agent |
| JP3263598B2 (ja) * | 1995-11-01 | 2002-03-04 | 有限会社ドット | 経鼻吸収用生理活性ペプチド組成物 |
| US5837266A (en) * | 1996-04-30 | 1998-11-17 | Hydromer, Inc. | Composition, barrier film, and method for preventing contact dermatitis |
| CH690719A5 (it) * | 1996-08-19 | 2000-12-29 | Rotta Res B V Amsterdam Swiss | Procedimento per la preparazione di sali misti della glucosamina. |
| AU4995597A (en) * | 1996-10-23 | 1998-05-15 | Vertex Pharmaceuticals Incorporated | Methods of using sucrose octasulfate to treat or prevent enveloped virus infection |
| GB9625193D0 (en) | 1996-12-04 | 1997-01-22 | Ml Lab Plc | Treatment of highly vascular tumours |
| AU1223099A (en) * | 1997-11-24 | 1999-06-15 | Zhongming Zeng | Pharmaceutical formulation for stimulating the growth of gram-positive bacil li and increasing the acidity in vagina and the use thereof |
| FI974321A0 (fi) | 1997-11-25 | 1997-11-25 | Jenny Ja Antti Wihurin Rahasto | Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa |
| WO1999043333A1 (en) * | 1998-02-27 | 1999-09-02 | The Althexis Company | Therapeutic and prophylactic uses of negatively charged substituted disaccharides |
| US5902800A (en) * | 1998-03-27 | 1999-05-11 | Glenpharma | Dextran formulations and method for treatment of inflammatory joint disorders |
| US7906153B2 (en) | 1998-04-08 | 2011-03-15 | Theta Biomedical Consulting & Development Co., Inc. | Anti-inflammatory compositions for treating multiple sclerosis |
| BR9806540C1 (pt) * | 1998-06-09 | 2001-05-08 | Akira Yoshitome | Produto farmacêutico para tratamento de hemofilia e de bronquite asmática |
| JP4439119B2 (ja) * | 1998-10-05 | 2010-03-24 | 株式会社ヤクルト本社 | 抗菌剤及びその製造法 |
| AU2007200916B2 (en) * | 1998-10-05 | 2009-09-17 | Kabushiki Kaisha Yakult Honsha | Antibacterial agents and process for producing the same |
| EP2258183A1 (en) * | 1998-12-22 | 2010-12-08 | The University of North Carolina at Chapel Hill | Compounds and uses for the treatment of airway diseases and for the delivery of airway drugs |
| US6964949B2 (en) | 2000-05-24 | 2005-11-15 | Shanghai Jiao Da Onlly Co., Ltd. | Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in the vagina and the use thereof |
| BRPI0101486B1 (pt) * | 2001-04-17 | 2017-09-19 | Cristália Produtos Químicos Farmacêuticos Ltda. | Pharmaceutical composition for topic use containing heparin for the treatment of skin or mucosal injuries caused by burns |
| US7285536B2 (en) | 2001-12-05 | 2007-10-23 | Yeda Research And Development Co., Ltd. | Anti-cancer therapeutic compounds |
| DE10161149B4 (de) * | 2001-12-12 | 2007-03-08 | Ursapharm Arzneimittel Gmbh & Co. Kg | Verwendung von Heparin-haltigem Ophthalmikum |
| AU2002366763A1 (en) * | 2001-12-13 | 2003-07-09 | Dia Pharmaceutical Co., Ltd. | Gel compositions for external use, pad materials and pad materials to be packed in blister containers |
| WO2003066001A2 (en) | 2002-02-07 | 2003-08-14 | The Trustees Of Columbia University In The City Of New York | Zinc salt compositions for the prevention of mucosal irritation from spermicides and microbicides |
| US7879365B2 (en) | 2002-02-07 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Zinc salt compositions for the prevention of dermal and mucosal irritation |
| US7265097B2 (en) | 2002-08-20 | 2007-09-04 | Chitogenics, Inc. | Methods of drug delivery using sulphated chitinous polymers |
| US20060234977A1 (en) * | 2003-01-23 | 2006-10-19 | Gina Wenham | Antiviral compostion comprising a sulphated glucose polymer and a bacteriostatic agent |
| US7244764B2 (en) | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US7414076B2 (en) | 2003-06-23 | 2008-08-19 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| BRPI0412675A (pt) | 2003-07-17 | 2006-10-03 | Univ Columbia | composições antimicrobianas contendo combinações sinergìsticas de compostos de amÈnio quaternário e óleos essenciais e/ou constituintes |
| ZA200700758B (en) | 2004-08-05 | 2008-08-27 | Ivax Drug Res Inst Ltd | Polysulfated glycosides and salts thereof |
| US20090215717A1 (en) * | 2004-08-05 | 2009-08-27 | Ivax Drug Research Institute Ltd. | Sulfated oligosaccharides |
| WO2006017727A2 (en) * | 2004-08-05 | 2006-02-16 | Ivax Corporation | Glycosides and salts thereof |
| BRPI0519243A2 (pt) | 2004-12-22 | 2009-01-06 | Neurochem Int Ltd | mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide |
| DE602005008964D1 (de) * | 2005-09-16 | 2008-09-25 | Italfar Societa A Responsabili | Wundheilende pharmazeutische Zusammensetzung enthaltend Sucralfat, Glycin, Aluminium Acetat und Vitamine |
| MX2008008213A (es) | 2005-12-22 | 2008-09-03 | Neurochem Int Ltd | Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias. |
| KR20080025900A (ko) * | 2006-09-19 | 2008-03-24 | (주) 서울바이오메드 | 글루코사민 또는 글루코사민 유도체를 포함하는 알레르기성결막염 치료용 조성물 및 이를 사용하여 알레르기성결막염을 치료하는 방법 |
| DK2089417T3 (da) | 2006-10-12 | 2015-03-23 | Bhi Ltd Partnership | Fremgangsmåder, forbindelser, sammensætninger og vehikler til afgivelse af 3-amion-1-propansulfonsyre |
| GB0622688D0 (en) | 2006-11-14 | 2006-12-27 | Diosamine Dev Corp | Novel compounds |
| GB2450087A (en) * | 2007-06-11 | 2008-12-17 | Diosamine Dev Corp | Use of sulphated saccharides in the treatment of inflammatory and/or auto-immune diseases |
| WO2010033408A1 (en) | 2008-09-17 | 2010-03-25 | Mcgrath Patrick D | Antimicrobial sucralfate paste methods and compositions |
| KR101669528B1 (ko) * | 2008-11-20 | 2016-10-26 | 라보라토리 데리바티 오르가니치 에스.피.아. | 헤파란 술페이트의 정제 방법 및 미용학적 및 피부학적 제제에서 그의 용도 |
| FR2953522B1 (fr) * | 2009-12-07 | 2012-03-09 | Fabre Pierre Dermo Cosmetique | Sucrose octasulfates de zinc, leur preparation et leurs applications pharmaceutiques et cosmetiques |
| FR2956322A1 (fr) * | 2010-02-17 | 2011-08-19 | Urgo Lab | Utilisation d'oligosaccharides polysulfates synthetiques comme agents de detersion d'une plaie. |
| CA2790682C (en) | 2010-03-03 | 2020-11-24 | Neocutis Sa | Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds |
| JP2014501730A (ja) * | 2010-12-01 | 2014-01-23 | ジ オーストラリアン ナショナル ユニバーシティ | ヒストン阻害 |
| ITMI20110033A1 (it) * | 2011-01-17 | 2012-07-18 | Biofarmitalia Spa | Composizione terapeutica mucoadesiva a base di acido ialuronico per la prevenzione e terapia di lesioni epiteliali, delle mucose del corpo umano |
| FR2975994B1 (fr) * | 2011-05-31 | 2015-03-06 | Fabre Pierre Dermo Cosmetique | Sucroses octasulfates de calcium, leur preparation et leurs applications pharmaceutiques et cosmetiques |
| FR2975993B1 (fr) * | 2011-05-31 | 2013-06-28 | Fabre Pierre Dermo Cosmetique | Sucroses octasulfates de magnesium, leur preparation et leurs applications pharmaceutiques et cosmetiques |
| FR2991876B1 (fr) * | 2012-06-13 | 2014-11-21 | Vivacy Lab | Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate |
| FR2993182B1 (fr) | 2012-07-13 | 2014-10-17 | Urgo Lab | Pansement a liberation prolongee d'actifs |
| US10716802B2 (en) | 2013-03-15 | 2020-07-21 | The Brigham And Women's Hospital, Inc. | Compounds to modulate intestinal absorption of nutrients |
| KR101649201B1 (ko) * | 2014-01-22 | 2016-08-18 | 대구가톨릭대학교산학협력단 | 오만둥이 유래 황산다당을 유효성분으로 함유하는 피부 미백 및 주름 개선용 화장료 조성물 |
| EP3352738B1 (en) | 2015-09-24 | 2024-01-17 | The Brigham and Women's Hospital, Inc. | Water-activated mucoadhesive compositions to reduce intestinal absorption of nutrients |
| FR3043556B1 (fr) * | 2015-11-17 | 2020-01-10 | Urgo Recherche Innovation Et Developpement | Utilisation de composes oligosaccharidiques pour activer l'angiogenese |
| FR3044555B1 (fr) | 2015-12-07 | 2020-03-06 | Centre National De La Recherche Scientifique - Cnrs - | Film comprenant un oligosaccharide polysulfate et un polycation et son procede de fabrication |
| FR3060392B1 (fr) * | 2016-12-19 | 2019-07-12 | Urgo Recherche Innovation Et Developpement | Utilisation de composes oligosaccharidiques pour activer l'epidermisation |
| IT201700047632A1 (it) * | 2017-05-03 | 2018-11-03 | Ricerfarma Srl | Composizioni topiche per mantenere e ripristinare l'omeostasi idrica della pelle |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4486416A (en) * | 1981-03-02 | 1984-12-04 | Soll David B | Protection of human and animal cells subject to exposure to trauma |
| FR2503563A1 (fr) * | 1981-04-09 | 1982-10-15 | Pos Lab | Composition pour collyre a base de sulfate de chondroitine a |
| DE3131811A1 (de) * | 1981-08-12 | 1983-04-21 | Serapharm - Michael Stroetmann, 4400 Münster | Heparinsalbe zur percutanen behandlung von thrombophlebitiden oder varizen |
| IT1189298B (it) * | 1982-06-18 | 1988-02-04 | Manetti & Roberts Italo Brit | Procedimento per produrre i glicosa minoglicani dermatansolfato ed eparan-solfato sostanzialmente puri e loro impiego farmaceutico |
| JPS5978116A (ja) * | 1982-10-27 | 1984-05-04 | Chugai Pharmaceut Co Ltd | スクラルフェ−ト製剤 |
| US4640912A (en) * | 1983-06-09 | 1987-02-03 | Hausman Marvin S | Administration of "active" chondroitin sulfate A and "active" chondroitin sulfate C or mixtures thereof to mammals including humans |
| DE3323389A1 (de) * | 1983-06-29 | 1985-01-10 | B. Braun Melsungen Ag, 3508 Melsungen | Auf schleimhaeute des mundes, der nase und/oder des rachens wirkende arzneimittel auf der basis von heparin und tensiden |
| AU555747B2 (en) * | 1983-08-09 | 1986-10-09 | Cilco Inc. | Chondroitin sulfate and sodium hyaluronate composition |
| CA1218601A (en) * | 1983-09-02 | 1987-03-03 | Angel B. Casillan | Sucralfate suspension |
| AU607690B2 (en) * | 1985-12-24 | 1991-03-14 | Marion Laboratories, Inc. | Use of synthetic sulfated saccharides to enhance wound healing |
| AU594765B2 (en) * | 1986-05-16 | 1990-03-15 | Chugai Seiyaku Kabushiki Kaisha | Sucralfate preparations for applications on esophagus mucosa |
| EP0254845A3 (en) * | 1986-06-10 | 1989-04-19 | Lescarden Inc. | Immune stimulation with chondroitin sulfate |
| DK505488D0 (da) * | 1987-12-21 | 1988-09-09 | Bar Shalom Daniel | Middel og anvendelse af samme |
-
1988
- 1988-09-09 DK DK505488A patent/DK505488D0/da not_active Application Discontinuation
- 1988-12-21 WO PCT/DK1988/000216 patent/WO1989005645A1/en not_active Ceased
- 1988-12-21 AU AU29146/89A patent/AU631529B2/en not_active Ceased
- 1988-12-21 WO PCT/DK1988/000217 patent/WO1989005646A1/en not_active Ceased
- 1988-12-21 DE DE3853365T patent/DE3853365T2/de not_active Expired - Fee Related
- 1988-12-21 KR KR1019890701562A patent/KR930003117B1/ko not_active Expired - Fee Related
- 1988-12-21 AT AT89901102T patent/ATE119778T1/de not_active IP Right Cessation
- 1988-12-21 DE DE3856442T patent/DE3856442T2/de not_active Expired - Fee Related
- 1988-12-21 EP EP89901102A patent/EP0394333B1/en not_active Expired - Lifetime
- 1988-12-21 JP JP1501021A patent/JPH04500797A/ja active Pending
- 1988-12-21 AT AT94202490T patent/ATE197546T1/de not_active IP Right Cessation
- 1988-12-21 EP EP94202490A patent/EP0640346B1/en not_active Expired - Lifetime
- 1988-12-21 EP EP89901101A patent/EP0420849A1/en not_active Withdrawn
- 1988-12-21 JP JP1501022A patent/JPH0739347B2/ja not_active Expired - Fee Related
- 1988-12-21 KR KR1019890701561A patent/KR900700108A/ko not_active Ceased
- 1988-12-21 AU AU29145/89A patent/AU2914589A/en not_active Abandoned
-
1990
- 1990-06-21 DK DK151590A patent/DK165357C/da not_active IP Right Cessation
- 1990-06-21 DK DK151690A patent/DK151690A/da not_active IP Right Cessation
-
1992
- 1992-01-17 DK DK005792A patent/DK169018B1/da not_active IP Right Cessation
-
1996
- 1996-03-28 HK HK56396A patent/HK56396A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0640346B1 (en) | 2000-11-15 |
| DK5792A (da) | 1992-01-17 |
| DK505488D0 (da) | 1988-09-09 |
| KR900700109A (ko) | 1990-08-11 |
| DE3853365T2 (de) | 1995-07-27 |
| ATE197546T1 (de) | 2000-12-15 |
| JPH0739347B2 (ja) | 1995-05-01 |
| KR900700108A (ko) | 1990-08-11 |
| AU2914689A (en) | 1989-07-19 |
| DK151590A (da) | 1990-08-14 |
| DK151590D0 (da) | 1990-06-21 |
| AU631529B2 (en) | 1992-12-03 |
| WO1989005645A1 (en) | 1989-06-29 |
| DK151690D0 (da) | 1990-06-21 |
| AU2914589A (en) | 1989-07-19 |
| KR930003117B1 (ko) | 1993-04-19 |
| EP0394333B1 (en) | 1995-03-15 |
| EP0394333A1 (en) | 1990-10-31 |
| HK56396A (en) | 1996-04-03 |
| ATE119778T1 (de) | 1995-04-15 |
| DK165357B (da) | 1992-11-16 |
| DE3856442T2 (de) | 2001-05-10 |
| WO1989005646A1 (en) | 1989-06-29 |
| JPH04500797A (ja) | 1992-02-13 |
| JPH04500798A (ja) | 1992-02-13 |
| DK151690A (da) | 1990-08-15 |
| DK5792D0 (da) | 1992-01-17 |
| DK165357C (da) | 1993-04-05 |
| EP0640346A1 (en) | 1995-03-01 |
| DE3853365D1 (de) | 1995-04-20 |
| EP0420849A1 (en) | 1991-04-10 |
| DE3856442D1 (de) | 2000-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK169018B1 (da) | Anvendelse af sulfaterede sukkerarter | |
| US5908836A (en) | Protecting skin from radiation damage using sulphated sugars | |
| CN108348577B (zh) | 贻贝粘蛋白产品及其抑制皮肤炎症的应用 | |
| US5529987A (en) | Hyaluronic acid-urea pharmaceutical compositions and uses | |
| CA2152398A1 (en) | Hyaluronic acid-urea pharmaceutical compositions and uses | |
| WO2004100923A1 (en) | The composition for external use by percutaneous administration | |
| US20040156875A1 (en) | Cosmetic composition based on zinc and cooper sulphates and sucralphate | |
| US11696907B2 (en) | Wound healing composition | |
| CN106491634B (zh) | 玻璃酸二甲基硅烷醇复合物及其组合物 | |
| CN105616296B (zh) | 一种杨枸花止痒护肤泥 | |
| CN112933214A (zh) | 一种促进伤口愈合的组合物 | |
| RU2092156C1 (ru) | Раствор для стимуляции репарации кожи "коллагель" | |
| CA2020199C (en) | Uses of sulphated sugars | |
| JP2723473B2 (ja) | 硫酸化糖類の用途 | |
| KR100963611B1 (ko) | 알긴산류 화합물을 포함하는 점안용 조성물 및 그의제조방법 | |
| RU2218907C1 (ru) | Композиция для ухода за кожей лица и веками | |
| DK174560B1 (da) | Anvendelse af sulfaterede sukkerarter til fremstilling af et præparat til behandling af skæl | |
| CA2020200A1 (en) | Use of sucralfate | |
| EP3087990B1 (en) | Gel-forming powder comprising sulfamonomethoxine and chitosan for treating wounds | |
| CN107596370A (zh) | 一种治疗宫颈糜烂的药物复方制剂及用途 | |
| CN100496508C (zh) | 一种聚甲酚磺醛凝胶剂、其制备方法及药物用途 | |
| CN105395527A (zh) | 一种海洋生物护伤喷膜剂的制备方法 | |
| AU664419B2 (en) | Use of sulphated sugars | |
| CN120053402A (zh) | 一种米诺环素和过氧苯甲酰的药物组合物及其制备方法和应用 | |
| JPWO2006121209A1 (ja) | 湿疹・皮膚炎群治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B1 | Patent granted (law 1993) | ||
| PUP | Patent expired |